Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

J&J Gains on Claims Its Booster Shot Raises Immunity Against Covid

Published 21/09/2021, 12:44
Updated 21/09/2021, 12:44
© Reuters.

© Reuters.

By Dhirendra Tripathi

Investing.com – Johnson & Johnson (NYSE:JNJ) stock traded more than 1% up in Tuesday’s premarket on encouraging results from a phase-III real-world study on a booster dose of its Covid-19 vaccine.

The company said its booster shot is 94% effective when administered two months after the first dose. It said the booster increases antibody levels by four to six times relative to one shot.

Boosters given six months after the first shot appear to give even higher protection, the company said. All rises were irrespective of age, the company said.

J&J’s Covid-19 vaccine is the only one approved by western economies that is administered with a single dose.

Around 14.8 million Americans have received the company’s single-dose vaccine so far. The study included 390,000 people who received the J&J Covid-19 vaccine.

An advisory committee on Friday recommended Pfizer (NYSE:PFE) booster shots to people 65 years and older, along with other vulnerable population groups. A final decision from the Food and Drug Administration is expected any day now. The panel voted against endorsing Covid-19 booster shots widely, a plan that the Biden administration favored.

The administration’s plans on boosters have received flak from various quarters, notably the World Health Organization, as much of the world is still unvaccinated, allowing the virus to spread and mutate freely in those countries.

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.